Article
Biochemistry & Molecular Biology
Ekachai Dumkliang, Boonnada Pamornpathomkul, Prasopchai Patrojanasophon, Tanasait Ngawhirunpat, Theerasak Rojanarata, Sutee Yoksan, Praneet Opanasopit
Summary: The study evaluated the immunization effect of mucoadhesive nanoparticles loaded with live attenuated Japanese encephalitis-chimeric virus vaccine through the intranasal route, demonstrating that intranasal immunization stimulated immune protection and enhanced mucosal immune response.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Article
Immunology
Zhongbing Qi, Jing Zhao, Yuhua Li, Bin Zhang, Shichuan Hu, Yanwei Chen, Jinhu Ma, Yongheng Shu, Yunmeng Wang, Ping Cheng
Summary: In this study, the researchers discovered that JEV-LAV had oncolytic activity against GBMs, inhibiting their growth in vivo. It also increased CD8+ T cell infiltration in tumor tissues and remodeled the immunosuppressive GBM microenvironment, improving the response of aPD-L1 blockade therapy. The safety of JEV-LAV intracerebral injection in animals supported its potential for clinical use in GBM treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Virology
Yi-Chin Fan, Yi-Ying Chen, Jo-Mei Chen, Chienjin Huang, Mei Huang, Shyan-Song Chiou
Summary: The expansion of genotype I (GI) Japanese encephalitis viruses (JEV) has raised concerns over the effectiveness of genotype III (GIII) virus-derived vaccines. This study used swine as a model to evaluate the effectiveness of GIII live-attenuated vaccines against GI virus infection.
Article
Immunology
Mya Myat Ngwe Tun, Aung Kyaw Kyaw, Khine Mya Nwe, Shingo Inoue, Kyaw Zin Thant, Kouichi Morita
Summary: A study conducted among monastic school children in Mandalay, Myanmar showed that 87% of students still had neutralizing antibodies against JEV six months after receiving the SA-14-14-2 live-attenuated vaccine. Antibody titers increased with age, with statistically significant differences noted across age groups.
Article
Multidisciplinary Sciences
Lorena Sanchez-Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma, Viktor Lemmens, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert Malengier-Devlies, Laurens Liesenborghs, Suzanne J. F. Kaptein, Carolien De Keyzer, Lindsey Bervoets, Sarah Debaveye, Madina Rasulova, Laura Seldeslachts, Li-Hsin Li, Sander Jansen, Michael Bright Yakass, Babs E. Verstrepen, Kinga P. Boszormenyi, Gwendoline Kiemenyi-Kayere, Nikki van Driel, Osbourne Quaye, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Ward Deboutte, Jelle Matthijnssens, Lotte Coelmont, Corinne Vandermeulen, Elisabeth Heylen, Valentijn Vergote, Dominique Schols, Zhongde Wang, Willy Bogers, Thijs Kuiken, Ernst Verschoor, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Vande Velde, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys, Johan Neyts, Hendrik Jan Thibaut, Kai Dallmeier
Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.
Article
Medicine, Research & Experimental
Enyue Fang, Xinyu Liu, Xiaohui Liu, Ming Li, Ling Wang, Miao Li, Zelun Zhang, Yuhua Li, Yongxin Yu
Summary: The study showed that neutralizing antibodies produced by JE-CV were slightly lower than SA14-14-2, and the protection conferred by JE-CV was considerably lower with low vaccine dose. JE-CV did not induce a specific T-cell response against JEV NS3, but did induce a potent antigen-specific T-cell response against the viral backbone vaccine YFV.
Article
Virology
Muhammad Naveed Anwar, Shuang Guo, Wang Xin, Muddassar Hameed, Abdul Wahaab, Xiaochun Ma, Aman Ullah Khan, Sajid Ur Rahman, Donghua Shao, Zongjie Li, Ke Liu, Beibei Li, Yafeng Qiu, Zhiyong Ma, Jianchao Wei
Summary: SD12-F120, a live-attenuated genotype I strain of Japanese encephalitis virus, showed good adaptation to growth in Vero cells after serial passaging. It provided complete protection against homologous strains but limited protection against heterologous strains, possibly due to differences in neutralizing antibody titers.
Article
Fisheries
Hiroaki Saito, Shungo Minami, Manami Yuguchi, Aiko Shitara, Hidehiro Kondo, Goshi Kato, Motohiko Sano
Summary: This study aimed to explore alternative vaccination protocols for the P7-P8 strain in goldfish, by testing different dilutions and exposure times for dipping and showering vaccination. The results showed that the showering vaccination protocol, which uses small amounts of vaccine culture and requires short labor time, may be a suitable alternative to the standard bath method in goldfish aquaculture.
Review
Immunology
Nathan B. Price, Charles Grose
Summary: Corticosteroids, especially in high dosages, may increase the risk of serious adverse events following live varicella and zoster vaccination. Studies have shown that patients receiving corticosteroids after vaccination are more prone to severe infectious complications, highlighting the importance of monitoring for such risks in clinical practice.
Article
Oncology
Tatsuro Jo, Ritsuko Kubota-Koketsu, Yohei Kaneko, Takahiro Sakai, Kazuhiro Noguchi, Sadaharu Irie, Masatoshi Matsuo, Jun Taguchi, Kuniko Abe, Kazuto Shigematsu
Summary: This study investigated whether vaccination with live attenuated varicella-zoster virus (VZV) can activate HTLV-1 Tax-specific cellular immune response in patients with ATLL. The results showed that after VZV vaccination, there was a significant increase in HTLV-1 Tax-specific CTLs percentage in aggressive-type ATLL patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Immunology
Kee Thai Yeo, Wan Ni Chia, Chee Wah Tan, Chengsi Ong, Joo Guan Yeo, Jinyan Zhang, Su Li Poh, Amanda Jin Mei Lim, Kirsten Hui Zhi Sim, Nursyuhadah Sutamam, Camillus Jian Hui Chua, Salvatore Albani, Lin-Fa Wang, Mei Chien Chua
Summary: The majority of lactating mothers had detectable SARS-CoV-2 antibody isotypes and neutralizing antibodies in serum and breastmilk, especially after the second dose of BNT162b2 vaccination. Transient, low levels of vaccine mRNA were detected in the serum of vaccinated mothers with occasional transfer to their breastmilk, but we did not detect evidence of infant sensitization. Importantly, the presence of breastmilk neutralizing antibodies likely provides a foundation for passive immunization of the breastmilk-fed infant.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Anurag Kalia, Mona Agrawal, Nimesh Gupta
Summary: The SA14-14-2 Japanese encephalitis (JE) vaccine induces robust GC responses and relies on CD4(+)T cells for protection, which can be enhanced by the presence of CD8(+)T cells. Lack of CD8(+)T cells impairs both CD4(+)T cell protective properties and the quality of antibody response to the vaccine.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Review
Immunology
Jue Hou, Weijian Ye, Jianzhu Chen
Summary: Dengue is a common mosquito-borne disease caused by four closely related viruses. Developing a vaccine that can protect against all four virus strains without adverse effects is a challenge. Several tetravalent live attenuated vaccine candidates have entered clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Virology
D. Scott Schmid, Congrong Miao, Jessica Leung, Michael Johnson, Adriana Weinberg, Myron J. Levin
Summary: The two HZ vaccines, RZV and ZVL, show different humoral responses, with RZV significantly boosting avidity to gE and neutralizing antibodies, providing longer-lasting immune memory.
JOURNAL OF VIROLOGY
(2021)
Article
Immunology
Dong-Ho Jo, Dohsik Minn, Jaegyun Lim, Ki-Deok Lee, Yu-Min Kang, Kang-Won Choe, Kwang-Nam Kim
Summary: The study found that antibody levels and neutralizing antibodies increased significantly shortly after the BNT162b2 vaccine was administered, but rapidly decreased four months after the second dose, regardless of gender or age. Further research is needed to determine the optimal interval for SARS-CoV-2 vaccinations.